At a glance
ClinicalIndex Comparison RecordN/ACompleted· 573 enrolled
Drug / intervention
dexamethasone 700 ug intravitreal implantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)
In Brief
An observational study evaluating dexamethasone 700 ug intravitreal implant for Macular Edema and Retinal Vein Occlusion. Completed, enrolled 573 participants across 1 site.
Detailed Summary
This study will evaluate the relationship between time since onset of macular oedema symptoms and the achievement of vision gain in patients prescribed OZURDEX®. All care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and local standard of medical care.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema, Retinal Vein Occlusion
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartApr 2012
Primary CompletionMar 2014
Study CompletionJun 2014
TodayJul 2026
First PostedApr 5, 2012
Enrollment StartApr 30, 2012
Primary CompletionMar 31, 2014
Study CompletionJun 30, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.2 years ago
Interventions
dexamethasone 700 ug intravitreal implantdrug
dexamethasone 700 ug intravitreal implant administered according to standard of care.